Biopharmas have $1.7 trillion to spend on deals this year, and big players like Novartis, Pfizer and Merck & Co. have made it pretty clear they’re on the hunt for acquisitions.
Merck might want Mirati. Novartis has put out a plea for small biotechs to swim toward its $154 billion pool. Pfizer is eyeing late-stage assets with a $175 billion hoard to help boost 2030 revenue by $25 billion. And Johnson & Johnson, with a new CEO at the helm, will be “more aggressive” with a $200 billion pile as the company sheds its consumer health unit.
After a slump in 2021, biopharma M&A is slated to pick up this year with an “innovation deficit” spurring shopping for new assets. Billions of dollars are obviously available for megadeals, and an endless sea of biotechs are giving shoppers a long list of options.
